Heart failure & cardiomyopathiesSecondary analysis
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants
- Secondary analysis of the DECLARE-TIMI 58 randomised trial
- whole-exome sequencing
- genetic subgroup analysis
Study context
- Population
- Adults with T2DM and increased CV risk with sequence data; carriers vs noncarriers of P/LP variants in high-confidence cardiomyopathy genes121 carriers
- Participants
- 12,685 adults
- Comparison
- Dapagliflozin vs placebo in carriers vs noncarriers of cardiomyopathy variants
- Primary endpoint
- Hospitalization for HF (HHF)
- Follow-up
- Median 4.2 years
Primary result
As reported in the abstract
HHF, by cardiomyopathy variant carrier status · median 4.2 years
Dapagliflozin vs PlaceboHazard ratio (95% CI)
carriers
0.18(0.04–0.86)
noncarriers
0.70(0.57–0.86)
- Absolute risk reduction, carriers
- 13.0%
- Absolute risk reduction, noncarriers
- 1.0%
Further findings
Hospitalization for HF (HHF) absolute risk reduction, no prior heart failure (HF) (subgroup)
- Absolute risk reduction, carriers without prior HF
- 12.8%
- Absolute risk reduction, noncarriers
- 0.6%
- 82% of carriers had no prior HF
- interaction P 0.01
Original publication
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants. Nat Med. Published 8 June 2026. doi:10.1038/s41591-026-04439-x
Summarised from the published abstract; every number is checked against it